Emerging virus infections “in a changing world · Emerging virus infections “in a changing...
Transcript of Emerging virus infections “in a changing world · Emerging virus infections “in a changing...
Emerging virus infections“in a changing world”
Animals as reservoirs of human viruses
Albert Osterhaus
Bruxelles June 2004
West Nile Yellow fever Dengue Avian influenza Lassa MeningitisJapanese encephalitis Ebola/Marburg Rift valley Polio Nipah SARS
Crimean-Congo HFVenez. Eq. encephalitis VHF HantaMonkeypox Enterovirus
Virus threats worldwide- 1996-2003, WHO outbreak reports -
Emerging virus infections in the last decennia- Part 1 -
Facilitated by changes in:
Social environment- Behaviour (taboos, mores, i.v. drug abuse)- Mobility (air travel, wars …)- Demography (population density, urbanisation…)- Public health measures (breakdown…)
Technology- Medical (transfusion, transplantation, vaccination)- Food production (recycling…)
Emerging virus infections in the last decennia- Part 2 -
Facilitated by changes in:
Ecology:- Animal contacts (wildlife, zoo, pets…)- Agriculture (deforestation…)- Fisheries (predator migration…)- Environmental pollution (immune suppression…)- Global warming (flora and fauna…)
Virus:- Mutation (host range, virulence…)- Recombination/reassortment
Bioterrorism?
Lentiviruses- Host range -
Influenza pandemics of the 20th century
Virus Subtype Name Est. # deaths
1918 H1N1 “Spanish Flu” > 40 million
1957 H2N2 “Asian Flu” > 1 million
1968 H3N2 “Hong Kong Flu” > 1 million
Bird markets- Asia -
Claas & Osterhaus, Nature Medicine 4: 1122-1123 (1998)
Human virusReassortant virus
Avian virus Avian virus
Influenza A virus- Man as a “mixing vessel” -
Highly pathogenic avian influenza (HPAI) seriously suspected clinically: February 28th 2003
Reports of conjunctivitis- By date of onset of symptoms -
Suspect A/H7 conjunctivitisInfluenza A-conjunctivitisConfirmed A/H7 conjunctivitis
Date of onset
June
12
Feb
28
0
5
10
15
20
25
# of
cas
es
Mar
7
Mar
14
Mar
21
Mar
28
Apr
4
Apr
11
Apr
18
Apr
25
May
2
May
9
May
16
May
23
May
30
Jun
6
Koopmans et al., Lancet 2004
H7N7 in The Netherlands- Fatal case chest X-ray upon admission -
X-ray fatal H7N7 infectionday of admission
Virus # substitutions inGene A/Netherlands/33/03 (conj.) A/Netherlands/219/03 (fatal case)
Segment Nucleotide Amino acid Nucleotide Amino acid1 (PB2) 2 0 8 5 (S79I,V297I,R355K,Q563R,E627K)2 (PB1) 0 0 2 03 (PA) 0 0 5 1(F666L)4 (HA) 0 0 4 3(I13S,A143T,K416R)5 (NP) 0 0 1 06 (NA) 0 0 5 4(N308S, A346V, T442A, P458S)7 (MA) 0 0 0 08 (NS) 1 1 (K126R)2 1 1(V137I)2
H7N7 in The Netherlands- Sequence analysis of full-length genomes -
1. Sequences were compared to those of A/Chicken/Netherlands/1/032. Both mutations in NS1
Fouchier et al., PNAS, 2004
?
?
H7N7 in The Netherlands- Chain of transmission -
LPAI
HPAI
Order Mononegavirales, family Paramyxoviridae
0.1
NiVHeV
TuV CDV RPVMV
hPIV3bPIV3
SeV
hPIV1
NDV
MuVSV5hPIV2
hMPVAPV
hRSV
bRSV
SV41
LPMV
Pneumovirinae
Paramyxovirinae Respirovirus
Rubulavirus
Morbillivirus
Metapneumovirus
Pneumovirus
DNA Maximum likelihood, Polymerase ORF
PDV
Avulavirus
Henipahvirus
- Pleiomorph
- Average size: 100-600 nm
- Envelope projections: 13-17 nm
- Paramyxovirus
Newly discovered paramyxovirus- Electron microscopy -
B.G. van den Hoogen et al.Nat. Med. 7:719-724, 2001
- (Young) children > 7-8 % of children with RTI?
- Immunocompromised individuals
- Elderly
- Normal individuals> 2-3 % of RTI in community surveillance studies
Human metapneumovirus- Risk groups -
Osterhaus and Fouchier, Lancet 2004
Severe acute respiratory syndrome (SARS)- A world-wide threat -
The same week: Hong Kong researchers announce fingings of Paramyxoviruses in SARS patients.Similar findings communicated from Canada through SARS etiology network
Novel coronavirus identified in SARS patients
SARS coronavirus phylogeny
P.Rota et al., Science, 2003
HCoV-NL: a fourth coronavirus of humans- phylogeny -
Full
geno
me
TM g
lyco
prot
ein
E
Rep
licas
e 1a
bM
atrix
Spik
eN
ucel
ocap
sid
Fouchier et al., PNAS 2004
SARS and the Koch’s postulates
Two viruses have been isolated from SARS patients: SCV and hMPV
Koch’s postulates modified for viruses by Rivers (1937):1. Isolation from diseased hosts
2. Cultivation in host cells
3. Proof of filterability
4. Production of comparable disease in host or related species
5. Reisolation of the virus
6. Detection of specific immune response
Cynomolgus monkeys (Macaca fascicularis)
Simultaneous SCV-hMPVinfection experiments:
•SCV alone•hMPV alone•SCV followed by hMPV
Fouchier et al.,Nature 2003
SARS coronavirus (SCV) in macaques
Histological lesions in lungs from cynomolgus macaques infected with SCV
Kuiken et al. The Lancet 2003
Time afterinoculation
(days)
02468
10121416
Throat
-++------
Nose
-++------
Faeces
N.T.N.T.
-------
IF
-N.T.N.T.N.T.N.T.
+N.T.N.T.
+
Throat
-++++----
Nose
-+++++---
Faeces
N.T.N.T.
+------
IF
-N.T.N.T.N.T.N.T.
+N.T.N.T.
+
Macaque # 3 Macaque # 4
SARS coronavirus in macaques
Exclusion of hMPV as the primary cause of SARS by macaque infection experiment
Koch’s postulates modified for viruses by Rivers:1.Isolation from diseased hosts2.Cultivation in host cells3.Proof of filterability4.No production of comparable disease in related species5.Reisolation of the virus6.Detection of specific immune response
SCV infected macaques subsequently inoculated with hMPV did not show disease exacerbation
Search for natural reservoir of SARS-CoV(Guan et al. 2003 Science)
111Raccoon dog
102Chinese ferret badger
366Himalayan palm civet
AntibodyPCR/
isolation
NSpecies
Hog badgers (3), beavers (3), domestic cats (3), Chinese hares (4), and Chinese muntjacs (2) all
tested negative.
Excretion of SCV in domestic cats and ferrets
SCV inoculated ferretsB
0 2 4 6 8 10 14 16 21 28
SCV exposed ferretsD
101
102
103
104
105
106
SCV inoculated catsA
N.D.
SCV
TCID
50/m
l
0 2 4 6 8 10 14 16 21 28101
102
103
104
105
106
SCV exposed catsC
N.D.
SCV
TCID
50/m
l
time (days)Martina et al. Nature, 2003.
Treatment of SARS-CoV infected macaqueswith pegylated interferon-α (Haagmans et al. 2004, Nature Medicine)
3 groups of cynomolgus macaquesControl (n = 4)Prophylactic (n = 4)Post-exposure (n = 4)
Treated with 3 mg/kg IFN, at-3, -1, +1, +3 dpi (prophylactic)+1, +3 (post-exposure)
Same infection protocol
Euthanasia at 4 dpi
Examination by:Pathology (gross, histology)ImmunohistochemistryRT-PCRVirus isolation
SARS-CoV excretion from pharynx
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
3 0 0
3 5 0
0 2 4 0 2 4 0 2 4 C o n tro l g ro u p
P ro p h yla c tic g ro u p
P o s t e xp o s u re g ro u p
D a y :* **
SC
V e
q/m
l
Haagmans et al., Nature Med. 2004
1 0 3
1 0 4
1 0 5
1 0 6
1 0 7
1 0 8
a
SCV
TCID
50/m
l
0
2 0
4 0
6 0
8 0
1 0 0b
SCV
infe
cted
cel
ls
(% S
CV
+m
icro
scop
ic fi
elds
)
0
1 0
2 0
3 0
4 0c
His
topa
thol
ogy
scor
e
C o n t r o l g r o u p
P o s t e x p o s u r e g r o u p
P r o p h y l a c t i c g r o u p
*
*
*
*
*
*
SARS-CoV replication, Ag-expression and histopathological lesions in lungs
Haagmans et al., Nature Med. 2004
A complex mix of socialsocial, technologicaltechnological, ecologicalecological and viralviral changes
Predisposes for the emergenceemergence of virus infections
Originating from animal reservoirsanimal reservoirs
Emerging virus infections- Conclusions 1 -
Extensive diagnosticdiagnostic and surveillancesurveillance networks
As well as novel vaccinevaccine- and antiviralantiviral development strategies
Should provide the safeguards to limit their impact
Emerging virus infections- Conclusions 2 -
Acknowledgements
Dept. Virology,Erasmus MC
Theo BestebroerBé NiemeyerGeorgina AronRobert Dias-d’UlloisGeert van AmerongenGerard van DoornumMartin SchuttenBert NiestersBart HaagmansByron MartinaGuus RimmelzwaanThijs KuikenRon FouchierAb Osterhaus
WHO & Members of the WHO SARS aetiology team
Centers for Disease Control & Prevention, Atlanta, USACentral Public Health Laboratory, London, UK
Public Health Laboratory Centre, Hongkong, SAR ChinaPrince of Wales Hospital, SAR China
Queen Mary Hospital, SAR ChinaSingapore General Hospital, Singapore
Federal Laboratories for Health Canada, Winnipeg, CanadaHealth Canada, Ottawa, Canada
Bernhard-Nocht Institute, Hamburg, GermanyInstitut Pasteur, Paris, France
National Institute of Infectious Disease, Tokyo, Japan
Emergingvirus infections
Department of Virology